PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review

Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in...

Full description

Bibliographic Details
Main Authors: Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier, Anthony Gonçalves
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
breast cancer
immunotherapy
PD1
PDL1
triple-negative breast cancer
Online Access:https://www.mdpi.com/2072-6694/11/7/1033

Similar Items

Similar Items